Tag: bellerophon therapeutics

January 28, 2019

Bellerophon to Present Clinical Data Supporting Actigraphy as a Clinically Meaningful Endpoint

Bellerophon Therapeutics (Nasdaq:BLPH) a clinical-stage biotherapeutics company, today announced that data from the Company’s ongoing INOpulse Phase 2b clinical trial...
January 13, 2019

5 Top Weekly NASDAQ Biotech Stocks: Index Up During JPM Week

Axsome Therapeutics, Checkpoint Therapeutics, Bellerophon Therapeutics, Enochian Bioscience and Equillium were last week's top gainers.
December 16, 2018

5 Top Weekly NASDAQ Biotech Stocks: Innovate Leads the Pack

Innovate Biopharmaceuticals, Aridis Pharmaceuticals, Imprimis Pharmaceuticals, Achaogen and SynthoRx were last week's top gainers.
November 18, 2018

5 Top Weekly NASDAQ Biotech Stocks: Cocrystal on Top

Cocrystal Pharma, Ra Pharmaceuticals, Avenue Therapeutics, Imprimis Pharmaceuticals and Nightstar Therapeutics were last week's top gainers on the NASDAQ Biotechnology...
November 7, 2018

Bellerophon Provides Business Update and Reports Third Quarter 2018 Financial Results

Bellerophon Therapeutics (Nasdaq: BLPH) a clinical-stage biotherapeutics company, today provided a business update and reported financial results for the third...
October 9, 2018

Bellerophon Updates Ongoing Phase 2b Trial

Bellerophon Therapeutics announced the completion of enrolment for its iNO-PF trial and said it expects top-line results in January 2019.
October 9, 2018

Bellerophon Provides Update on INOpulse Phase 2b Clinical Program for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease

Bellerophon Therapeutics (Nasdaq:BLPH) a clinical-stage biotherapeutics company, today provided an update on the Company’s ongoing Phase 2b randomized, double-blind, placebo-controlled...